CAR T-Cell Therapy for Relapsed/Refractory CLL
2 意见
• 07/14/23
0
0
嵌入
The panelists provide insight on the use of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia and the TRANSCEND CLL-004 trial of liso-cel (JCAR017) in relapsed/refractory disease.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论